ARCHIVES

Carfilzomib Demonstrates Clinical Benefit Rate of 64%

This article is from The Cancer Letter archive.

Vol. 34 No. 12 | December 30, 2011

Download PDF Visit The Full Archive

Related Articles

NCI-Funded Trials Show Aspirin Reduces Recurrence of Polyps

March 28, 2003

Rosenberg Starts New Study With TIL; LAK-IL-2 Costs Clarified

November 28, 1986

Cancer Letter Adds Associate Editor

July 19, 1985

Phase II Trial of BIND-014 Shows Anti-Tumor Activity in Q3W Arm

November 28, 2014

NCI To Pilot Text Chat On CancerNet And CIS Sites.

September 29, 2000

NTP Board Okays Modification Of Bioassay Protocols

April 9, 1982